Key Updates from the 2025 San Antonio Breast Cancer Symposium
GLP-1 receptor agonists—commonly known by brand names such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound®—have rapidly changed the landscape of medical weight loss and metabolic disease. Originally developed for diabetes management, these medications are now widely prescribed for obesity, insulin resistance, and cardiometabolic risk reduction.
As their use expands, an important and increasingly common question arises in oncology clinics:
Are GLP-1 medications safe for breast cancer patients and survivors—and can they offer benefits beyond weight loss?
Based on current evidence:
- GLP-1 receptor agonists do not appear to increase breast cancer recurrence
- They are effective for weight loss in breast cancer survivors
- They may improve metabolic health, cardiovascular risk, and quality of life
- Side effects are generally manageable but require monitoring
That said, GLP-1 therapy is not appropriate for every patient. Contraindications, treatment timing, cancer subtype, bone health, and gastrointestinal tolerance must all be considered.
Emerging research suggests that, when carefully selected and medically supervised, GLP-1 receptor agonists may play a valuable role in breast cancer survivorship, metabolic health, and supportive cancer care. However, the data are nuanced, and individualized decision-making is essential.
This article reviews what we currently know—and what we are still learning—about GLP-1 therapy in breast cancer.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone involved in glucose regulation, appetite signaling, and energy balance. GLP-1 receptor agonists mimic this hormone and work by:
- Reducing appetite and food intake
- Slowing gastric emptying
- Improving insulin sensitivity
- Lowering blood glucose
- Promoting sustained weight loss
In addition to metabolic effects, GLP-1 medications demonstrate anti-inflammatory, cardioprotective, and possibly immunomodulatory properties, which have prompted investigation into their role in cancer care.
Why Metabolic Health Is Central to Breast Cancer Outcomes
Metabolism and breast cancer are deeply interconnected. Estrogen is not only a reproductive hormone—it is also a key regulator of body composition, insulin sensitivity, lipid metabolism, and inflammation.
After menopause—or during estrogen-suppressing treatment—many women experience:
- Weight gain, particularly visceral (abdominal) fat
- Increased insulin resistance
- Higher rates of pre-diabetes and type 2 diabetes
- Dyslipidemia and cardiovascular risk
- Chronic inflammation
For women with hormone receptor–positive (HR+) breast cancer, endocrine therapies such as aromatase inhibitors (anastrozole, letrozole, exemestane) and tamoxifen are highly effective at reducing recurrence and improving survival. However, these therapies can also worsen metabolic dysfunction, often making weight loss extremely difficult despite diet and exercise.
Excess weight and insulin resistance are not merely cosmetic concerns—they are associated with:
- Higher recurrence risk in HR+ breast cancer
- Increased cardiovascular mortality
- Reduced quality of life and physical function
This is where GLP-1 medications have generated significant interest.
GLP-1 Medications and Early Breast Cancer (DCIS)
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer with variable risk of progression to invasive disease. A large retrospective study of more than 6,000 women with DCIS receiving hormonal therapy found that those taking GLP-1 medications had better survivorship outcomes:
- Lower rates of progression to invasive breast cancer (4.1% vs 10.8%)
- Lower progression to stage IV cancer (3.8% vs 10.6%)
- Improved 5-year overall survival (93.5% vs 85.7%)
These findings are hypothesis-generating and suggest a potential protective association, though randomized controlled trials are needed to confirm causality and mechanism.
GLP-1 Medications and Weight Loss in Breast Cancer Patients on Endocrine Therapy
One of the most clinically relevant concerns is whether GLP-1 medications remain effective in women receiving endocrine therapy, where weight loss resistance is common.
What recent studies show
A retrospective study of 110 postmenopausal women with HR+ breast cancer receiving endocrine therapy evaluated weight loss outcomes after starting pharmacologic weight-loss agents, primarily GLP-1 receptor agonists.
Key findings included:
- Average weight loss of nearly 19 pounds within the first 3 months
- Continued weight reduction of 30–40 pounds by 6–9 months
- Weight loss plateauing after approximately 9–12 months
- Degree of weight loss comparable to the general population
- No new safety signals identified
Importantly, many patients had been on endocrine therapy for several years before initiating GLP-1 treatment, suggesting that these medications may help overcome long-standing metabolic resistance.
For breast cancer survivors struggling with weight gain despite lifestyle optimization, this represents a meaningful therapeutic option when used appropriately.
GLP-1 Therapy in Triple-Negative Breast Cancer: A More Complex Picture
Triple-negative breast cancer (TNBC) is biologically distinct and relies heavily on chemotherapy and immunotherapy rather than hormonal treatment.
Some early studies suggested that GLP-1 use might be associated with lower pathologic complete response (pCR) rates in TNBC patients receiving neoadjuvant chemo-immunotherapy. In contrast, a study conducted at a medical center with a high prevalence of obesity and a predominantly Hispanic population found no significant difference in treatment response between GLP-1 users and non-users.
These conflicting findings suggest that:
- Population differences (ethnicity, obesity prevalence, metabolic health) may matter
- GLP-1 effects may vary by tumor biology
- More large, multi-center studies are needed
At this time, GLP-1 therapy in TNBC should be considered cautiously and collaboratively with the oncology team.
GLP-1 Therapy During Chemotherapy: Emerging Supportive-Care Benefits
Chemotherapy-related side effects account for a significant portion of cancer-related morbidity and treatment interruptions. A large real-world analysis involving 5,685 patient examined breast cancer patients receiving chemotherapy with or without concurrent GLP-1 therapy.
Patients using GLP-1 medications experienced significantly lower rates of:
- Anemia, neutropenia, and thrombocytopenia
- Sepsis and infection
- Nausea, vomiting, diarrhea, and mucositis
- Fatigue and neuropathy
- Venous thromboembolism
- Cardiac complications
- Elevated liver enzymes
These findings suggest that GLP-1 receptor agonists may improve treatment tolerability and physiologic resilience during chemotherapy. GLP-1 medications may help patients tolerate chemotherapy better, supporting future research into their role in reducing treatment side effects and improving overall outcomes.
Survival Outcomes and GLP-1 Use in Breast Cancer
Perhaps one of the most compelling findings comes from large database analyses evaluating all-cause mortality in obese breast cancer patients receiving endocrine therapy.
Across both younger and older age groups, GLP-1 use was associated with a significant reduction in mortality compared to matched patients not receiving GLP-1 therapy.
This association persisted after adjusting for:
- Age
- Comorbidities
- Diabetes
- Cancer stage
- Prior chemotherapy
Important nuance
While survival outcomes improved, GLP-1 use was also associated with increased reporting of certain endocrine-therapy–related side effects, including:
- Hot flashes
- Gastrointestinal symptoms
- Joint pain
- Mood changes
- Bone density concerns in older patients
This underscores a critical principle: GLP-1 therapy must be individualized, with careful monitoring and supportive management of side effects.
Carevivor Medical Weight Loss Program:
A Personalized, Oncology-Informed Approach to GLP-1 Therapy
At our clinic, GLP-1 medications are never prescribed in isolation. They are integrated into a comprehensive metabolic and survivorship program that considers:
- Cancer subtype and treatment history
- Current endocrine or chemotherapy regimen
- Insulin resistance and cardiometabolic risk
- Nutrition, exercise, and body composition
- Bone density and muscle preservation
- Quality of life and long-term survivorship goals
This individualized approach allows us to optimize benefits while minimizing risk—beyond the standard of care.
The Bottom Line
GLP-1 receptor agonists represent a powerful tool in modern metabolic medicine. For selected breast cancer patients and survivors, they may offer benefits that extend beyond weight loss, including improved treatment tolerance, metabolic health, and possibly survival.
However, these medications must be used thoughtfully, guided by oncology-informed clinicians, and tailored to the individual patient.
As research continues to evolve, GLP-1 therapy may become an increasingly important component of comprehensive breast cancer survivorship care.
Schedule a Consultation
If you are a breast cancer patient or survivor experiencing weight gain, insulin resistance, or metabolic changes related to cancer treatment, our team can help determine whether GLP-1–based medical weight management is appropriate for you.
At Carevivor, we provide an oncologist-directed, holistic weight loss program created specifically for breast cancer survivors. Our comprehensive program includes advanced metabolic testing, weekly medical weight-loss injections, targeted nutritional supplementation, and non-invasive laser abdominal fat reduction therapies—all included in one affordable monthly membership.
Take the next step toward restoring your metabolic health and survivorship wellness. Call 410-740-7444 today to schedule your consultation.